<DOC>
	<DOCNO>NCT02692716</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate cardiovascular safety oral semaglutide subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Cardiovascular Safety Oral Semaglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female diagnose type 2 diabetes Age least 50 year screen presence cardiovascular disease , age least 60 year screen presence least one cardiovascular risk factor Current previous ( within 90 day prior screen ) treatment GLP1 ( glucagonlike peptide1 ) receptor agonist , DPP4 ( dipeptidyl peptidase4 ) inhibitor pramlintide Family personal history multiple endocrine neoplasia type 2 ( MEN 2 ) medullary thyroid carcinoma ( MTC ) History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Subjects presently classified New York Heart Association ( NYHA ) Class IV heart failure Planned coronary , carotid peripheral artery revascularisation know day screen Any following : myocardial infarction , stroke hospitalisation unstable angina transient ischaemic attack within past 60 day prior screen Chronic intermittent hemodialysis peritoneal dialysis severe renal impairment ( correspond eGFR ( glomerular filtration rate , estimate ) 30 mL/min/1.73 m^2 ) History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer carcinoma situ )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>